| ［1］ |
Musette P, Janela B. New insights into drug reaction with eosinophilia and systemic symptoms pathophysiology［J］. Front Med （Lausanne）, 2017,4:179. doi: 10.3389/fmed.2017.00179.
|
| ［2］ |
Skowron F, Bensaid B, Balme B, et al. Drug reaction with eosinophilia and systemic symptoms （DRESS）: clinicopa⁃thological study of 45 cases［J］. J Eur Acad Dermatol Venereol, 2015,29（11）:2199⁃2205. doi: 10.1111/jdv.13212.
|
| ［3］ |
Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives［J］. J Am Acad Dermatol, 2013,68（5）:693.e1⁃e14. doi: 10.1016/j.jaad.2013.01.033.
|
| ［4］ |
Shiohara T, Kano Y, Takahashi R, et al. Drug⁃induced hyper⁃sensitivity syndrome: recent advances in the diagnosis, patho⁃genesis and management［J］. Chem Immunol Allergy, 2012,97:122⁃138. doi: 10.1159/000335624.
|
| ［5］ |
Wu X, Yang F, Chen S, et al. Clinical, viral and genetic characteristics of drug reaction with eosinophilia and systemic symptoms （DRESS） in Shanghai, China［J］. Acta Derm Venereol, 2018,98（4）:401⁃405. doi: 10.2340/00015555⁃2867.
|
| ［6］ |
Wang L, Mei XL. Drug reaction with eosinophilia and systemic symptoms: retrospective analysis of 104 cases over one decade［J］. Chin Med J （Engl）, 2017,130（8）:943⁃949. doi: 10.4103/0366⁃6999.204104.
|
| ［7］ |
Sasidharanpillai S, Sabitha S, Riyaz N, et al. Drug reaction with eosinophilia and systemic symptoms in children: a prospective study［J］. Pediatr Dermatol, 2016,33（2）:e162⁃e165. doi: 10.1111/pde.12803.
|
| ［8］ |
Ferner RE. Adverse drug reactions in dermatology［J］. Clin Exp Dermatol, 2015,40（2）:105⁃109. doi: 10.1111/ced. 12572.
|
| ［9］ |
Walsh SA, Creamer D. Drug reaction with eosinophilia and systemic symptoms （DRESS）: a clinical update and review of current thinking［J］. Clin Exp Dermatol, 2011,36（1）:6⁃11. doi: 10.1111/j.1365⁃2230.2010.03967.x.
|
| ［10］ |
Niu J, Jia Q, Ni Q, et al. Association of CD8+ T lymphocyte repertoire spreading with the severity of DRESS syndrome［J］. Sci Rep, 2015,5:9913. doi: 10.1038/srep09913.
|
| ［11］ |
Phillips EJ, Chung WH, Mockenhaupt M, et al. Drug hyper⁃sensitivity: pharmacogenetics and clinical syndromes［J］. J Allergy Clin Immunol, 2011,127（3 Suppl）:S60⁃S66. doi: 10.1016/ j.jaci.2010.11.046.
|
| ［12］ |
Ksouda K, Affes H, Mahfoudh N, et al. HLA⁃A*31:01 and carbamazepine⁃induced DRESS syndrom in a sample of North African population［J］. Seizure, 2017,53:42⁃46. doi: 10.1016/j.seizure.2017.10.018.
|
| ［13］ |
Ng CY, Yeh YT, Wang CW, et al. Impact of the HLA⁃B（*）58:01 allele and renal impairment on allopurinol⁃induced cutaneous adverse reactions［J］. J Invest Dermatol, 2016,136（7）:1373⁃1381. doi: 10.1016/j.jid.2016.02.808.
|
| ［14］ |
Yang F, Gu B, Zhang L, et al. HLA⁃B*13:01 is associated with salazosulfapyridine⁃induced drug rash with eosinophilia and systemic symptoms in Chinese Han population［J］. Pharmacogenomics, 2014,15（11）:1461⁃1469. doi: 10.2217/pgs. 14.69.
|
| ［15］ |
Zhang FR, Liu H, Irwanto A, et al. HLA⁃B*13:01 and the dapsone hypersensitivity syndrome［J］. N Engl J Med, 2013,369（17）:1620⁃1628. doi: 10.1056/NEJMoa1213096.
|
| ［16］ |
Gonçalo M, Coutinho I, Teixeira V, et al. HLA⁃B*58:01 is a risk factor for allopurinol⁃induced DRESS and Stevens⁃Johnson syndrome/toxic epidermal necrolysis in a Portuguese population［J］. Br J Dermatol, 2013,169（3）:660⁃665. doi: 10.1111/bjd. 12389.
|
| ［17］ |
Yue Z, Sun Y, Wang C, et al. Amino acid variants of HLA⁃DRB1 confer susceptibility to dapsone hypersensitivity syndrome in addition to HLA⁃B*13:01［J］. J Invest Dermatol, 2018,138（5）:1101⁃1106. doi: 10.1016/j.jid.2017.11.027.
|
| ［18］ |
Lin CY, Wang CW, Hui CR, et al. Delayed⁃type hypersensitivity reactions induced by proton pump inhibitors: a clinical and in vitro T⁃cell reactivity study［J］. Allergy, 2018,73（1）:221⁃229. doi: 10.1111/all.13235.
|
| ［19］ |
Avancini J, Maragno L, Santi CG, et al. Drug reaction with eosinophilia and systemic symptoms/drug⁃induced hypersensi⁃tivity syndrome: clinical features of 27 patients［J］. Clin Exp Dermatol, 2015,40（8）:851⁃859. doi: 10.1111/ced.12682.
|
| ［20］ |
Ishida T, Kano Y, Mizukawa Y, et al. The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome［J］. Allergy, 2014,69（6）:798⁃805. doi: 10.1111/all.12410.
|
| ［21］ |
Kano Y, Tohyama M, Aihara M, et al. Sequelae in 145 patients with drug⁃induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions （ASCAR）［J］. J Dermatol, 2015,42（3）:276⁃282. doi: 10.1111/1346⁃8138.12770.
|
| ［22］ |
Ang CC, Wang YS, Yoosuff EL, et al. Retrospective analysis of drug⁃induced hypersensitivity syndrome: a study of 27 patients［J］. J Am Acad Dermatol, 2010,63（2）:219⁃227. doi: 10.1016/j.jaad.2009.08.050.
|
| ［23］ |
Matsuda H, Saito K, Takayanagi Y, et al. Pustular⁃type drug⁃induced hypersensitivity syndrome/drug reaction with eosino⁃philia and systemic symptoms due to carbamazepine with systemic muscle involvement［J］. J Dermatol, 2013,40（2）:118⁃122. doi: 10.1111/1346⁃8138.12028.
|
| ［24］ |
Ardern⁃Jones MR. Atypical erythema multiforme is a prognostic indicator of severe hepatic dysfunction in Dress （Drug Reaction with Eosinophilia and Systemic Symptoms）［J］. Br J Dermatol, 2013,168（2）:234⁃235. doi: 10.1111/bjd.12191.
|
| ［25］ |
Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases［J］. Arch Dermatol, 2010,146（12）:1373⁃1379. doi: 10.1001/archdermatol. 2010.198.
|
| ［26］ |
Kardaun SH, Sidoroff A, Valeyrie⁃Allanore L, et al. Variability in the clinical pattern of cutaneous side⁃effects of drugs with systemic symptoms: does a DRESS syndrome really exist?［J］. Br J Dermatol, 2007,156（3）:609⁃611. doi: 10.1111/j.1365⁃2133. 2006.07704.x.
|
| ［27］ |
Skowron F, Bensaid B, Balme B, et al. Comparative histological analysis of drug⁃induced maculopapular exanthema and DRESS［J］. J Eur Acad Dermatol Venereol, 2016,30（12）:2085⁃2090. doi: 10.1111/jdv.13832.
|
| ［28］ |
Kim DH, Koh YI. Comparison of diagnostic criteria and determination of prognostic factors for drug reaction with eosinophilia and systemic symptoms syndrome［J］. Allergy Asthma Immunol Res, 2014,6（3）:216⁃221. doi: 10.4168/aair.2014.6.3. 216.
|
| ［29］ |
Shiohara T, Kano Y. Drug reaction with eosinophilia and systemic symptoms （DRESS）: incidence, pathogenesis and management［J］. Expert Opin Drug Saf, 2017,16（2）:139⁃147. doi: 10.1080/14740338.2017.1270940.
|
| ［30］ |
Chen YC, Chang CY, Cho YT, et al. Long⁃term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan［J］. J Am Acad Dermatol, 2013,68（3）:459⁃465. doi: 10.1016/j.jaad.2012.08.009.
|
| ［31］ |
Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part II. Management and therapeutics［J］. J Am Acad Dermatol, 2013,68（5）:709.e1⁃e9. doi: 10.1016/j.jaad.2013.01.032.
|
| ［32］ |
Funck⁃Brentano E, Duong TA, Bouvresse S, et al. Therapeutic management of DRESS: a retrospective study of 38 cases［J］. J Am Acad Dermatol, 2015,72（2）:246⁃252. doi: 10.1016/j.jaad. 2014.10.032.
|
| ［33］ |
Marcus N, Smuel K, Almog M, et al. Successful intravenous immunoglobulin treatment in pediatric severe DRESS syndrome［J］. J Allergy Clin Immunol Pract, 2018,6（4）:1238⁃1242. doi: 10.1016/j.jaip.2017.10.016.
|
| ［34］ |
朱伟芳, 李炎冬, 斯子翔, 等. 静脉注射丙种球蛋白和糖皮质激素治疗药物超敏综合征的疗效观察［J］. 中华急诊医学杂志, 2013,22（9）:1054⁃1056. doi: 10.3760/cma.j.issn.1671⁃0282. 2013.09.031.
|
| ［35］ |
陈玲玲, 路丹丹, 施辛, 等. 肿瘤坏死因子α拮抗剂治疗一例伴嗜酸性粒细胞增多和系统症状药疹的临床观察［J］.中华皮肤科杂志, 2013,46（9）:621⁃625. doi: 10.3760/cma.j.issn.0412⁃4030.2013.09.003.
|
| ［36］ |
王松, 尉晓冬, 许爱娥, 等. 药物超敏反应综合征后发生白癜风二例［J］. 中华皮肤科杂志, 2012,45（6）:447⁃448. doi: 10.3760/cma.j.issn.0412⁃4030.2012.06.027.
|
